18 Jan 2026
byJairia Dela Cruz
For young women with a pathogenic variant in BRCA1 or BRCA2, initiating hormone replacement therapy following surgical menopause does not appear to significantly increase the risk of breast cancer, with oestrogen-alone therapy even conferring protection, according to a study.